A study of effectiveness of addition of drug teneligliptin to metformin, glimepiride, pioglitazone combination in type II diabetic patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20200258Keywords:
Glimepiride, Metformin, Pioglitazone, Teneligliptin, Type II diabetesAbstract
Background: Diabetes is a most prevalent chronic disease and has reached to alarming stage in almost all developed and developing countries. Worldwide approximately four hundred millions of people are living with diabetes and it is a leading cause of death. Aims and objectives is to study effectiveness of addition of drug Teneligliptin to Metformin, Glimepiride, Pioglitazone combination in type II Diabetic patients.
Methods: This was a cross sectional study carried out in the department of Medicine of a tertiary health care centre during the one year period i.e. January 2017 to January 2018 in the type II diabetic patients. Out of all type II diabetic patients 40 patients who were on the treatment for hypoglycemia with drugs Metformin, Glimepiride, Pioglitazone were selected out of these randomly 20 patients were continued on the previous treatment (Group B) and remaining 20 were given additional drug Teneligliptin (Group A). The statistical analysis was done by unpaired t-test and chi-square test analyzed by SPSS 19 version of software.
Results: In this study Authors have seen that the average age in both the groups was comparable i.e. 36.78±6.74 and 38.92±5.87 (p>0.05, t=1.24, df=38), the sex ration was also similar in both the group (p>0.43, χ2=0.43, df=1) and the HbA1C was comparable at 1st Wk. 10±4.56 - 9.87±3.42 (p>0.05, t=1.023, df=38) and 4th Wk. 8±5.23 - 9.67±4.52 (p>0.05, t=1.0804, df=38) but significantly differed at 8th Wk. 7.12±2.34 - 9.92±3.56 (p<0.01, t=3.82, df=38), 12th Wk. 5.98±1.98 - 9.24±2.79 (p<0.001, t=4.26, df=38) respectively in Group A and B.
Conclusions: It can be concluded from this study that the addition of Teneligliptin significantly reduced the HbA1c level at the end of 4th wk. and hence superior to conventional Metformin, Glimepiride, Pioglitazone only combination treatment.
References
Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation. 2015.
American Diabetes Association. 1. Strategies for improving care. Diab care. 2016 Jan 1;39(Supplement 1):S6-12.
American Diabetes Association. 3. Foundations of care and comprehensive medical evaluation. Diab Care. 2016 Jan 1;39(Supplement 1):S23-35.
Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?. Endocrine. 2013 Aug 1;44(1):47-58.
Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, Metab Synd Obes: Targ Ther. 2013;6:187.
Scott LJ. Teneligliptin: a review in type 2 diabetes. Clini Drug Invest. 2015 Nov 1;35(11):765-72.
Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Diabetes, Metab Synd Obes: Targ Ther. 2016;9:251.
Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987 Dec 5;330(8571):1300-4.
Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999 Jan 1;48(1):86-93.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995 Sep 1;44(9):1126-31.
Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998 Nov 1;47(11):1663-70.
Eto T, Inoue S, Kadowaki T. Effects of once‐daily teneligliptin on 24‐h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obes Metab. 2012 Nov;14(11):1040-6.
Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes, Obes Metab. 2013 Sep;15(9):810-8.
Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes/ Metab Res Rev. 2009 Nov;25(8):705-16.
Idris I, Donnelly R. Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug. Diabetes, Obes Metab. 2007 Mar;9(2):153-65.
Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006 May 1;55:S20-7.
Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009 Jul 31;325(5940):607-10.
Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Ferreira JC. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011 Mar 1;2(1):32-44.
Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clini Pract. 2010 Sep 1;89(3):216-23.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled study with an open‐label, long‐term extension. Diabetes, Obes Metab. 2014 May;16(5):418-25.
